Vicore Pharma Holding AB ADS (VCRE)

• Market cap: $3.49B
• 1 day: -2.06%
• 5 days: -9.56%
• 1 month: -23.75%
• 3 months: -23.75%
• 6 months: -23.75%
• Year to date: -23.75%
• 1 year: -23.75%
• 5 years: -23.75%
• 10 years: -23.75%
• Sector: Healthcare
• Industry: Biotechnology

About: Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.